Quanterix stock jumped about 8% to US$2.63 after earnings, a sharp move for a company that came into this week with double digit declines over the past month. The market is reacting to a very different story compared with the old high growth diagnostics promise. The headline this quarter is margin and cash discipline. Quanterix posted Q2 revenue of US$32.9 million while reporting a sizeable net loss and cutting full year revenue guidance to a range of US$142 million to US$148 million. The stock is now trading on whether this tighter cost and cash stance can buy the time the story needs.

Is Quanterix now a genuine bargain at roughly 0.8x P/S compared with peers on 4x to 5x, or is the worsening loss profile a warning sign investors should not ignore? Compare that trade off directly in our valuation analysis for Quanterix.

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$32.9 million vs. US$24.5 million (reported increase of about 34%)
• Net Income/Loss, Q2 2026 vs. Q2 2025: loss of US$48.9 million vs. loss of US$30.0 million (loss widened)
• Basic EPS, Q2 2026 vs. Q2 2025: loss of US$1.04 per share vs. loss of US$0.77 per share (loss per share increased)
• Non GAAP Gross Margin, Q2 2026 vs. Q2 2025: about 47.9% vs. about 41.9% (improved by roughly 600 basis points)

Prefer clear charts instead of another dense earnings release? See Quanterix’s full financial picture, with a focus on its valuation, in an easy-to-scan visual format via our company report for Quanterix.

Quanterix bull case hinges on execution milestones

Bulls argue that Quanterix is turning high-end technology into a healthier, more recurring business built on Simoa, spatial platforms and diagnostics. The latest quarter gives mixed evidence. Non GAAP gross margin improved to about 47.9%, roughly 600 basis points higher, which supports the idea that Akoya integration and cost work are helping unit economics. Lucent AD Complete volumes increased from a small base and diagnostics partner revenue reached US$1.6 million, so the Alzheimer’s test is starting to show some traction. Management also reports higher Accelerator bookings, which points to underlying research demand despite weaker project sizes. However, pro forma revenue that includes Akoya declined around 23% and both Simoa and Spatial instruments fell, which means the larger installed base and cross sell thesis is not yet visible in the top line.

Bear case focuses on growth reset and cash burn

Bears worry that Quanterix is facing slower adoption, high cash use and a longer road to profitability. The cut to 2026 revenue guidance to US$142 million to US$148 million from US$169 million to US$174 million directly supports concerns about a growth reset. Pro forma revenue contraction of about 23% and weaker Simoa and Spatial instruments show that pressure is broad, not just a single product issue. The net loss of US$48.9 million and adjusted EBITDA loss of roughly US$10 million, plus a goodwill impairment of US$26.9 million, reinforce the view that profitability is still distant. Management now targets cash flow breakeven in 2027 instead of late 2026 and expects higher cash usage in Q3, which aligns with fears about extended cash burn even after US$85 million of annualized cost synergies.

After another guidance cut and a longer path to breakeven, are these setbacks isolated or part of a deeper issue? Review the risk analysis for Quanterix which shows 2 important warning signs.

Stay Ahead With Simply Wall St

With Quanterix resetting guidance and refocusing on margins and cash, price swings can open up opportunities or signal rising risk. Register for free with Simply Wall St and add Quanterix to your Watchlist to track the share price against fair value and identify an entry point that matches your plan. Once you are invested, use the Portfolio Command Center to cut through market noise and keep on top of the most important developments across all your holdings. Round it out by tapping into the Community to see how other investors are thinking about the story so you can spot potential catalysts or red flags early and stay ahead of the market.

Seeking Alternatives Beyond Quanterix Today

Fresh ideas can move fast. Some stocks are building quiet momentum while others are dropping back under the radar for now. Scan these curated picks before the crowd and act now.

• Spot companies quietly building steady strength and filter for resilient balance sheets using the curated list of solid balance sheet and fundamentals stocks (50 results).
• Ride potential breakout trends by zeroing in on curated growth stories on the 20 high quality undiscovered gems while they are still flying under the radar for now.
• Target consistent income by reviewing hand picked high yield opportunities in the 8 dividend fortresses before their prices are caught up by yield hungry buyers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.